Risk communication of study drug side effects: An evaluation of informed consent forms from ClinicalTrials.gov
Patient Education and Counseling · 2025
DOI: 10.1016/j.pec.2025.109261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Patient Education and Counseling, 2025. Verfasst von Chandler Coleman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie Inc., North Chicago, IL, USA. Electronic address: chandler.colem…. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Communication, Informed Consent, Consent Forms. Die Arbeit nennt 31 Literaturangaben. Gefördert von: AbbVie.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie Inc., North Chicago, IL, USA. Electronic address: chandler.coleman@abbvie.com.
- Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie Inc., North Chicago, IL, USA.
Förderung
- AbbVie
Zitieren
APA
Coleman, C., Jokinen, O., Duhig, J., Best, A., & Scarazzini, L. (2025). Risk communication of study drug side effects: An evaluation of informed consent forms from ClinicalTrials.gov. Patient Education and Counseling. https://doi.org/10.1016/j.pec.2025.109261
Vancouver
Coleman C, Jokinen O, Duhig J, Best A, Scarazzini L. Risk communication of study drug side effects: An evaluation of informed consent forms from ClinicalTrials.gov. Patient Education and Counseling. 2025. doi:10.1016/j.pec.2025.109261
BibTeX
@article{Coleman2025,
author = {Coleman, Chandler and Jokinen, Owen and Duhig, James and Best, Andrea and Scarazzini, Linda},
title = {Risk communication of study drug side effects: An evaluation of informed consent forms from ClinicalTrials.gov},
journal = {Patient Education and Counseling},
year = {2025},
doi = {10.1016/j.pec.2025.109261}
}
EUVIMED